Immunoresponsive Autonomic Neuropathy in Sjögren Syndrome-Case Series and Literature Review.
Brent P Goodman
https://pubmed.ncbi.nlm.nih.gov/28379880/Actively Recruiting
Led by Endeavor Health · Updated on 2026-01-09
20
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating the use of an intravenous immunoglobulin IVIG called Panzyga to treat patients with small fiber neuropathy SFN, a condition that causes pain and nerve damage. This study focuses on patients with autoimmune SFN who have specific antibodies TS-HDS, FGFR-3, or Plexin D1. While Panzyga is approved for other immune-related conditions, it has not yet been approved for SFN. The purpose is to see if Panzyga can improve nerve fiber density and reduce pain in these patients. Participants will be randomly assigned to receive either Panzyga IVIG or a placebo. Those in the treatment group will receive 2gkg of IVIG every four weeks over two days 1gkg on each day for a total of six doses over 24 weeks. The placebo group will get saline infusions on the same schedule. This double-blind trial compares the effects of IVIG against placebo over six months. During the study, participants will undergo skin biopsies before and after treatment to measure nerve fiber density, which is the primary outcome after 24 weeks. Secondary assessments include pain ratings, disability scales, symptom questionnaires, and neurological exams at baseline and week 28. Patients will be monitored regularly to track symptoms and safety throughout the trial, which is expected to complete by February 2028.
CONDITIONS
IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
A
Anna Pham
M
May Aunaetitrakul
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Endeavor Health
Lead Sponsor
Octapharma USA, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | IVIG (Panzyga 10%) | Placebo Infusion |
|---|---|---|
| What it is | Intravenous immune globulin (IVIG, Panzyga 10%) given as an infusion, tested for autoimmune small fiber neuropathy with associated autoantibodies. | A saline infusion (0.9% sodium chloride), volume-matched to IVIG, with no active immune therapy. |
| Role in the study | Tested as the investigational treatment to evaluate its effect on nerve fiber density and symptoms. | Serves as the control group to determine the effectiveness and risks of IVIG in this population. |
| Primary use or purpose | Assessing the impact of IVIG on nerve fiber density and symptom severity in people with autoimmune small fiber neuropathy linked to specific autoantibodies. | Provides a baseline for comparison, measuring changes that occur without active immunotherapy. |
| How it is given or performed | IVIG is administered intravenously as an infusion in a clinical setting. | Placebo saline is infused intravenously in the same way as the active treatment. |
| Evidence to support its use | Case series and retrospective studies suggest some patients with immune-mediated small fiber neuropathy and these autoantibodies may benefit from IVIG, but high-quality randomized trial evidence is limited and inconsistent. | A placebo infusion does not contain active therapy and is not expected to improve nerve fiber density or symptoms in autoimmune SFN. |
| Important limitations | Previous evidence supporting IVIG is mainly from small studies and case series; randomized controlled trial data are still lacking and long-term outcomes are unclear. | A placebo does not offer active disease treatment and may not reflect responses to other supportive or symptomatic therapies that patients receive outside a clinical trial. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive intravenous infusions of either IVIG or placebo every 4 weeks over 2 days for a total of 24 weeks.
6 treatment visits (in-person), each over 2 days
Duration - 4 weeks
Participants are assessed for changes in pain, disability, and neuropathy symptoms after treatment completion.
1 follow-up visit (in-person)
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Brent P Goodman
https://pubmed.ncbi.nlm.nih.gov/28379880/Martine J H Peters, Mayienne Bakkers, Ingemar S J Merkies...
https://pubmed.ncbi.nlm.nih.gov/23997150/Antoine Gaillet, Karine Champion, Jean-Pascal Lefaucheur...
https://pubmed.ncbi.nlm.nih.gov/31520801/Lawrence A Zeidman
https://pubmed.ncbi.nlm.nih.gov/38771228/Jinny O Tavee, Karen Karwa, Zubair Ahmed...
https://pubmed.ncbi.nlm.nih.gov/28318820/N Souayah, R L Chin, T H Brannagan...
https://pubmed.ncbi.nlm.nih.gov/19049545/B T A de Greef, J G J Hoeijmakers, C M L Gorissen-Brouwers...
https://pubmed.ncbi.nlm.nih.gov/29112785/J Robinson Singleton, Billie Bixby, James W Russell...
https://pubmed.ncbi.nlm.nih.gov/18844788/S Kovvuru, Y C Cardenas, A Huttner...
https://pubmed.ncbi.nlm.nih.gov/32068339/Kamran Darabi, Omar Abdel-Wahab, Walter H Dzik
https://pubmed.ncbi.nlm.nih.gov/16686841/Endeavor Health
Lead Sponsor
Octapharma USA, Inc.
Collaborating Sponsor